SMMT divests investigational antibiotic ridinilazole to Biossil for upfront cash, milestone payments and royalties as it sharpens its focus on oncology.

In recent commentary, Laughing Water Capital pointed to the past year’s commercial progress of Liquidia’s pulmonary hypertension therapy YUTREPIA and the company’s intent to broaden its approved uses, while a delayed court ruling has eased fears that ongoing litigation could force the drug off the market. At the same time, third-party analysis classifies Liquidia as fundamentally above average yet trading below some intrinsic value estimates, even as significant insider share sales add a...

Liquidia is expanding the use of its pulmonary hypertension drug YUTREPIA into additional indications after early commercial traction. Ongoing patent litigation with United Therapeutics has moved in a direction that appears favorable for Liquidia, with a delayed ruling reducing the risk that YUTREPIA is removed from the market. These developments could affect the opportunity for NasdaqCM:LQDA shareholders by influencing the size and durability of YUTREPIA's addressable market. Liquidia...

Agenus surges after securing up to $340M in financing to fund its phase III ROBBIN colon cancer study and extend its cash runway if warrants are exercised.

Laughing Water Capital, an investment management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The second quarter was exceptionally good for the portfolio, with Class A investment in Laughing Water Capital returning approximately 39.8% net of all fees and expenses, bringing the YTD return to approximately 33.6% net. […]

LQDA's Yutrepia posts a strong commercial debut, but sustaining growth will hinge on standing out in the crowded PAH market as competition intensifies.

CGON climbs as cretostimogene nears a planned 2026 BLA filing, posts encouraging phase II data. It maintains a cash position that supports operations through 2029.